ARTA
XLRN

A.R.T. Advisors’s Acceleron Pharma XLRN Stock Holding History

A.R.T. Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-46,410
Closed -$2.25M – 1831
2018
Q2 		$2.25M Buy
+46,410
New +$1.69M 0.09% 322
2017
Q4 		– Sell
-12,702
Closed -$474K – 1781
2017
Q3 		$474K Buy
+12,702
New +$441K 0.02% 847
2017
Q1 		– Sell
-19,100
Closed -$487K – 1813
2016
Q4 		$487K Buy
+19,100
New +$605K 0.03% 760
2015
Q1 		– Sell
-9,323
Closed -$363K – 1787
2014
Q4 		$363K Buy
+9,323
New +$325K 0.01% 1032
2014
Q2 		– Sell
-8,202
Closed -$282K – 1606
2014
Q1 		$282K Buy
+8,202
New +$370K 0.01% 1007

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

A.R.T. Advisors's XLRN Position: Q3 2018 in Review

A.R.T. Advisors sold out of Acceleron Pharma (XLRN) in Q3 2018, closing a stake of 46,410 shares — an estimated $2.25M sold.

A.R.T. Advisors first reported a position in XLRN in Q1 2014 and held it in 5 quarters. The position peaked at $2.25M in Q2 2018. 167 funds tracked by Wall St. Rank hold XLRN as of Q3 2018.

  • A.R.T. Advisors reported no remaining Acceleron Pharma position as of Q3 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 46,410 Acceleron Pharma shares in Q3 2018, an estimated $2.25M.
  • A.R.T. Advisors first reported a position in Acceleron Pharma in Q1 2014 and held it in 5 quarters.
  • A.R.T. Advisors's Acceleron Pharma position peaked at $2.25M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2018.

Based on A.R.T. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.